Angiopoietin-1 Mimetic Nanoparticles for Restoring the Function of Endothelial Cells as Potential Therapeutic for Glaucoma.
Angpt-1 mimetic
POAG
Schlemm’s canal
Tie2
angiopoietin 1
eNOS
glaucoma
nanoparticles
peptide
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
24 Dec 2021
24 Dec 2021
Historique:
received:
25
11
2021
revised:
16
12
2021
accepted:
21
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
A root cause for the development and progression of primary open-angle glaucoma might be the loss of the Schlemm's canal (SC) cell function due to an impaired Angiopoietin-1 (Angpt-1)/Tie2 signaling. Current therapeutic options fail to restore the SC cell function. We propose Angpt-1 mimetic nanoparticles (NPs) that are intended to bind in a multivalent manner to the Tie2 receptor for successful receptor activation. To this end, an Angpt-1 mimetic peptide was coupled to a poly(ethylene glycol)-poly(lactic acid) (PEG-PLA) block co-polymer. The modified polymer allowed for the fabrication of Angpt-1 mimetic NPs with a narrow size distribution (polydispersity index < 0.2) and the size of the NPs ranging from about 120 nm (100% ligand density) to about 100 nm (5% ligand density). NP interaction with endothelial cells (HUVECs, EA.hy926) as surrogate for SC cells and fibroblasts as control was investigated by flow cytometry and confocal microscopy. The NP-cell interaction strongly depended on the ligand density and size of NPs. The cellular response to the NPs was investigated by a Ca
Identifiants
pubmed: 35056075
pii: ph15010018
doi: 10.3390/ph15010018
pmc: PMC8780450
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : BR3566/3-3
Organisme : Deutsche Forschungsgemeinschaft
ID : FU734/4-3
Références
Angew Chem Int Ed Engl. 2014 May 12;53(20):5093-6
pubmed: 24700480
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):803-814
pubmed: 29392327
Blood. 2008 Apr 15;111(8):4145-54
pubmed: 18252863
Nat Rev Dis Primers. 2016 Sep 22;2:16067
pubmed: 27654570
Invest Ophthalmol Vis Sci. 2011 Dec 09;52(13):9438-44
pubmed: 22039240
J Control Release. 2013 Apr 10;167(1):76-84
pubmed: 23369761
J Ocul Biol. 2013 Jun;1(1):3
pubmed: 24364042
Mol Cell. 2010 Mar 12;37(5):643-55
pubmed: 20227369
Int J Nanomedicine. 2010 Nov 26;5:1057-65
pubmed: 21170353
ACS Appl Mater Interfaces. 2020 Aug 5;12(31):34689-34702
pubmed: 32639709
Am J Physiol Lung Cell Mol Physiol. 2011 Jun;300(6):L851-62
pubmed: 21421750
Pharmaceutics. 2020 Jul 27;12(8):
pubmed: 32727014
J Clin Invest. 2017 Oct 2;127(10):3594-3597
pubmed: 28920923
Exp Eye Res. 2008 Apr;86(4):543-61
pubmed: 18313051
Macromol Biosci. 2020 Apr;20(4):e1900427
pubmed: 32077622
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4376-4381
pubmed: 28396439
J Cell Biol. 2005 Apr 25;169(2):239-43
pubmed: 15851516
Biomed Res Int. 2015;2015:141905
pubmed: 26557650
ACS Appl Mater Interfaces. 2015 May 20;7(19):10374-85
pubmed: 25909493
Am J Hosp Pharm. 1985 Jul;42(7):1568-71
pubmed: 4025356
Invest Ophthalmol Vis Sci. 2014 Nov 13;55(12):8067-76
pubmed: 25395486
Cytokine Growth Factor Rev. 2013 Dec;24(6):579-92
pubmed: 23838360
J Exp Pharmacol. 2021 Feb 25;13:197-212
pubmed: 33664600
J Drug Deliv. 2013;2013:374252
pubmed: 23533769
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5547-52
pubmed: 15060279
Expert Opin Ther Targets. 2017 Nov;21(11):1037-1050
pubmed: 28952395
Nanotechnology. 2020 Mar 27;31(13):132002
pubmed: 31770746
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
Am J Pathol. 2003 Jun;162(6):1927-36
pubmed: 12759249
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):692-706
pubmed: 26903228
J Sex Med. 2013 Dec;10(12):2912-27
pubmed: 23937122
Nat Commun. 2017 Jul 18;8:16106
pubmed: 28719590
Trends Mol Med. 2013 Jan;19(1):31-9
pubmed: 23182855
J Clin Invest. 2017 Oct 2;127(10):3877-3896
pubmed: 28920924
Invest Ophthalmol Vis Sci. 2007 Feb;48(2):715-26
pubmed: 17251470
Nanoscale. 2017 Apr 6;9(14):4787-4792
pubmed: 28345718
Drug Discov Today. 2019 Aug;24(8):1606-1613
pubmed: 30905679
ACS Appl Mater Interfaces. 2019 Jan 9;11(1):1311-1320
pubmed: 30521749
Circ Res. 2005 Jun 24;96(12):1282-90
pubmed: 15920022
Exp Eye Res. 1989 Jan;48(1):117-30
pubmed: 2920779
EMBO Rep. 2004 Mar;5(3):262-7
pubmed: 14978510
Prog Retin Eye Res. 2021 Jul;83:100922
pubmed: 33253900
Transl Vis Sci Technol. 2020 Mar 18;9(4):16
pubmed: 32818103
J Funct Biomater. 2015 Sep 21;6(3):963-85
pubmed: 26402712
Tissue Eng Part A. 2009 Jun;15(6):1269-80
pubmed: 18939935
Biol Direct. 2016 Oct 21;11(1):55
pubmed: 27769290
Prog Retin Eye Res. 2015 Jan;44:86-98
pubmed: 25223880